Get the Stockscreener App
57.56
1.88%
1.06
After Hours:
57.56
Hologic Inc stock is traded at $57.56, with a volume of 6.82M.
It is up +1.88% in the last 24 hours and down -6.89% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$56.50
Open:
$56.27
24h Volume:
6.82M
Relative Volume:
2.47
Market Cap:
$13.20B
Revenue:
$4.03B
Net Income/Loss:
$789.50M
P/E Ratio:
17.29
EPS:
3.33
Net Cash Flow:
$1.15B
1W Performance:
+0.70%
1M Performance:
-6.89%
6M Performance:
-28.47%
1Y Performance:
-23.17%
1-Day Range:
$55.89
$57.75
1-Week Range:
$55.89
$59.02
52-Week Range:
$55.89
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
57.56 | 13.20B | 4.03B | 789.50M | 1.15B | 3.33 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
How Is The Market Feeling About Hologic? - Benzinga
CureMetrix Mammogram Software Expands FDA Clearance, Validated on GE, Hologic Platforms - Imaging Technology News
Virology Testing Market Detailed In New Research Report 2025 | - openPR.com
Hyperpigmentation Treatment Devices Market Projected - openPR.com
Breast Lesion Localization Methods Market Detailed In New - openPR.com
Biopsy Devices Market Set to Witness Significant Growth - openPR.com
Mizuho Securities Cuts Hologic Price Target to $75 From $83, Maintains Outperform Rating - marketscreener.com
Sentinel Node Biopsy Market Growth in 2025 Driven by Precision - openPR.com
Hologic (HOLX): Mizuho Adjusts Target Price Ahead of Q1 | HOLX Stock News - GuruFocus
Sentinel Node Biopsy Market to Witness Remarkable Growth with - openPR.com
BofA Reduces Price Target for Hologic (HOLX) Amid Industry Headw - GuruFocus
Why Hologic (HOLX) Outpaced the Stock Market Today - Yahoo Finance
What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate? - Yahoo Finance
Fluoroscopy Devices Market Is Booming Worldwide with Positive - openPR.com
Breast Cancer Brachytherapy Market Future Business - openPR.com
Immunoassay Analyzers Market Size to Hit USD 10.16 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
X-ray Machine Manufacturing Market Generated Opportunities, - openPR.com
Hologic stock hits 52-week low at $57.36 amid market shifts - Investing.com India
Hologic stock hits 52-week low at $57.36 amid market shifts By Investing.com - Investing.com South Africa
Non-Invasive Cancer Diagnostics Market to Witness Massive - openPR.com
Q4 Earnings Outperformers: Hologic (NASDAQ:HOLX) And The Rest Of The Medical Devices & SuppliesImaging, Diagnostics Stocks - Yahoo Finance
Analyzing Hologic, Inc. v. Stepp: Key takeaways - Eversheds Sutherland
Histology And Cytology Market Is Booming Worldwide 2025-2032 | - openPR.com
Digital X-ray Devices Market to Witness Massive Growth by 2032 | - openPR.com
Virology Testing Market to Witness Remarkable Growth with - openPR.com
RBC Cuts Price Target on Hologic to $75 From $83, Keeps Sector Perform Rating - MarketScreener
Hologic (HOLX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Hologic adds Solventum CFO McMillan to its board - MassDevice
Hologic Brings In New Leadership: A Signal To Stay Put With The Stock? - Barchart.com
Hologic Brings in New Leadership: A Signal to Stay Put With the Stock? - Yahoo Finance
Hologic Onboards Wayde McMillan to its Board of Directors - World Business Outlook
Wayde McMillan Elected to Hologic Board of Directors - citybiz
Hologic adds Wayde McMillan to its Board of Directors By Investing.com - Investing.com South Africa
Hologic Expands Board with New Director Appointment - TipRanks
Hologic adds Wayde McMillan to its Board of Directors - Investing.com
Wayde Mcmillan Elected To Hologic Board Of Directors - MarketScreener
Wayde McMillan Elected to Hologic Board of Directors – Company Announcement - Financial Times
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025 - MarketScreener
Biopsy Devices Market Projected To Witness Massive Growth, - openPR.com
Groupama Asset Managment Acquires 21,037 Shares of Hologic, Inc. (NASDAQ:HOLX) - MarketBeat
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hologic Inc Stock (HOLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Sale |
76.34 |
24,856 |
1,897,482 |
27,957 |
2.53%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):